Ida Hovdenak Jakobsen1, Mette Moustgaard Jeppesen2, Sébastien Simard3, Henriette Vind Thaysen4, Søren Laurberg4, Therese Juul4. 1. Department of Surgery, Aarhus University Hospital, Tage Hansens Gade 2, 8000, Aarhus C, Denmark. idajak@rm.dk. 2. Department of Gynaecology and Obstetrics, Odense University Hospital, J.B. Winsløws Vej 4, 5000, Odense C, Denmark. 3. Department of Health Sciences, University of Quebec in Chicoutimi (UQAC), 555, boul. de l'Université, Chicoutimi, Quebec, Canada. 4. Department of Surgery, Aarhus University Hospital, Tage Hansens Gade 2, 8000, Aarhus C, Denmark.
Abstract
PURPOSE: The Fear of Cancer Recurrence Inventory (FCRI) is a multidimensional measure for fear of cancer recurrence (FCR). The aim of this study was to assess the psychometric properties of the translated Danish version of the FCRI in a population of colorectal cancer patients. METHODS: The English version of the FCRI was forward-backward translated into Danish and pilot tested in a gynaecological cancer population. The psychometric properties of the FCRI were assessed in terms of responsiveness, test-retest reliability and discriminative and convergent validity in a population of colorectal cancer patients by asking them to complete questionnaires at three time points during follow-up. Clinical FCR was defined as ≥ 16 at the FCRI short form. RESULTS: The participation rate was 57%. A low association was found between higher scores on the FCRI and younger age (r = - 0.29, p = 0.02). A moderate correlation was found between the FCRI score and a measure for worry traits (r = 0.49, p < 0.001). Mean difference in total FCRI score was statistically significant between 'pre-scan' and 'postscan' (p < 0.001), thus indicating that the FCRI was responsive to change. The FCRI score showed good test-retest reliability (intraclass correlation = 0.84). CONCLUSION: The Danish version of the FCRI is a reliable and responsive measure for FCR in colorectal cancer patients and shows acceptable discriminative and convergent validity. IMPLICATIONS FOR CANCER SURVIVORS: A valid measure for FCR is crucial in order to identify patients with a need for special attention or interventions for high levels of FCR and to improve future research into FCR among cancer survivors.
PURPOSE: The Fear of Cancer Recurrence Inventory (FCRI) is a multidimensional measure for fear of cancer recurrence (FCR). The aim of this study was to assess the psychometric properties of the translated Danish version of the FCRI in a population of colorectal cancerpatients. METHODS: The English version of the FCRI was forward-backward translated into Danish and pilot tested in a gynaecological cancer population. The psychometric properties of the FCRI were assessed in terms of responsiveness, test-retest reliability and discriminative and convergent validity in a population of colorectal cancerpatients by asking them to complete questionnaires at three time points during follow-up. Clinical FCR was defined as ≥ 16 at the FCRI short form. RESULTS: The participation rate was 57%. A low association was found between higher scores on the FCRI and younger age (r = - 0.29, p = 0.02). A moderate correlation was found between the FCRI score and a measure for worry traits (r = 0.49, p < 0.001). Mean difference in total FCRI score was statistically significant between 'pre-scan' and 'postscan' (p < 0.001), thus indicating that the FCRI was responsive to change. The FCRI score showed good test-retest reliability (intraclass correlation = 0.84). CONCLUSION: The Danish version of the FCRI is a reliable and responsive measure for FCR in colorectal cancerpatients and shows acceptable discriminative and convergent validity. IMPLICATIONS FOR CANCER SURVIVORS: A valid measure for FCR is crucial in order to identify patients with a need for special attention or interventions for high levels of FCR and to improve future research into FCR among cancer survivors.
Entities:
Keywords:
Cancer survivorship; Colorectal cancer; Fear of recurrence; Inventory; Translation, validity and responsiveness
Authors: S C Leeson; K Beaver; N P M Ezendam; R Mačuks; P L Martin-Hirsch; T Miles; M M Jeppesen; P T Jensen; P Zola Journal: Eur J Obstet Gynecol Reprod Biol Date: 2017-01-19 Impact factor: 2.435
Authors: Alice B Kornblith; Mark Powell; Meredith M Regan; Samantha Bennett; Carolyn Krasner; Beverly Moy; Jerry Younger; Annekathyrn Goodman; Ross Berkowitz; Eric Winer Journal: Psychooncology Date: 2007-10 Impact factor: 3.894
Authors: Lidwine B Mokkink; Caroline B Terwee; Donald L Patrick; Jordi Alonso; Paul W Stratford; Dirk L Knol; Lex M Bouter; Henrica C W de Vet Journal: Qual Life Res Date: 2010-02-19 Impact factor: 4.147
Authors: A M Stiggelbout; J C de Haes; R Vree; C J van de Velde; C M Bruijninckx; K van Groningen; J Kievit Journal: Br J Cancer Date: 1997 Impact factor: 7.640
Authors: José A E Custers; Marieke F M Gielissen; Stephanie H V Janssen; Johannes H W de Wilt; Judith B Prins Journal: Support Care Cancer Date: 2015-06-25 Impact factor: 3.603
Authors: Yvonne L Luigjes-Huizer; Nina M Tauber; Gerry Humphris; Nadine A Kasparian; Wendy W T Lam; Sophie Lebel; Sébastien Simard; Allan Ben Smith; Robert Zachariae; Yati Afiyanti; Katy J L Bell; José A E Custers; Niek J de Wit; Peter L Fisher; Jacqueline Galica; Sheila N Garland; Charles W Helsper; Mette M Jeppesen; Jianlin Liu; Roxana Mititelu; Evelyn M Monninkhof; Lahiru Russell; Josée Savard; Anne E M Speckens; Sanne J van Helmondt; Sina Vatandoust; Nicholas Zdenkowski; Marije L van der Lee Journal: Psychooncology Date: 2022-04-07 Impact factor: 3.955